Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) announced that CEO Faraz Ali will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, to discuss the company's mission to discover, develop, and deliver potentially curative therapies for heart disease.

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Chief Executive Officer, will present at the 42^nd Annual J.P. Morgan Healthcare Conference on January 11, 2024, at 9:45 am PT.

The live presentation will be webcast and may be accessed from the Investors section of Tenaya’s website. A replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.

About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Leveraging its integrated and interrelated Gene Therapy, Cellular Regeneration and Precision Medicine platforms and proprietary core capabilities, the company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. Tenaya’s most advanced candidates include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor being initially developed for heart failure with preserved ejection fraction (HFpEF). Tenaya also has multiple early-stage programs progressing through preclinical development. For more information, visit www.tenayatherapeutics.com.

Contacts Michelle Corral VP, Corporate Communications and Investor Relations IR@tenayathera.com

Investors Anne-Marie Fields Stern Investor Relations Annemarie.fields@sternir.com

What is the mission of Tenaya Therapeutics, Inc. (NASDAQ: TNYA)?

Tenaya Therapeutics, Inc. aims to discover, develop, and deliver potentially curative therapies that address the underlying causes of heart disease.

When will CEO Faraz Ali present at the 42nd Annual J.P. Morgan Healthcare Conference?

CEO Faraz Ali will present on January 11, 2024, at 9:45 am PT.

Where can the live presentation be accessed?

The live presentation can be accessed from the Investors section of Tenaya's website.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.